arrow_back Back to App

Drug Shortage Prevention: Faster Warnings, Better Access

New rules aim to prevent shortages of critical drugs in the United States. Manufacturers will need to report supply issues more quickly, allowing for earlier responses and ensuring continuous access to medication for citizens. This is intended to enhance health security and the availability of essential medicines.
Key points
Drug manufacturers must report supply issues, including increased demand, at least 6 months in advance or immediately in urgent cases.
The act covers life-saving, life-sustaining drugs, and those used for debilitating diseases, emergencies, and surgeries.
Increased transparency in drug supply chains through more frequent reports from manufacturers on ingredient sources.
Information on potential drug shortages will be shared with physician, health provider, and patient organizations.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_2665
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2025-08-01
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Drug Shortage Prevention Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_2665.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-08-01.

What are the main provisions?

Key points include:

  • Drug manufacturers must report supply issues, including increased demand, at least 6 months in advance or immediately in urgent cases.
  • The act covers life-saving, life-sustaining drugs, and those used for debilitating diseases, emergencies, and surgeries.
  • Increased transparency in drug supply chains through more frequent reports from manufacturers on ingredient sources.
  • Information on potential drug shortages will be shared with physician, health provider, and patient organizations.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health